The Modern Role of Beta-Blockers in Cardiovascular Medicine
The book provides a concise much-needed update of beta-blockers use cardiovascular area (particularly hypertension and heart failure). It will uncover the clinical inaccuracies of how the UK NICE Committee have "got it wrong" in their recent pronouncements on BBs and hypertension. Beta-blockers (BBs) are a large and important family of therapeutic agents with primary use is in cardiovascular medicine. The therapeutic areas that BB covers include: Ischemic Heart Disease, Hypertension, Heart Failure and Arrhythmias. Explanation of the role of BBs in the treatment of hypertension and why the UK Health Authority (The NICE Committee) have "got it wrong" A current update of the vital role of beta-blockers in the treatment of heart failure, and why some beta-blockers are "ineffective" Provides a total and current update of the role of beta-blockers in cardiovascular medicine.
What people are saying - Write a review
We haven't found any reviews in the usual places.
BetaBlockers and their Effects upon Ischemic Heart Disease Peripheral Vascular Disease Noncardiac Surgery and the Atheromatous Process
BetaBlockers and Hypertension
BetaBlockers and Cardiac Arrhythmias
Other editions - View all
ACE inhibitor acute myocardial infarction adrenaline adrenoceptor agents amlodipine angina antiarrhythmic antihypertensive aortic ARBs artery disease atenolol beneﬁt beta-blockers Beta-Blockers in Clinical bisoprolol blockers blood ﬂow blood pressure captopril Cardiol Cardiovasc Pharmacol carvedilol chronic Circulation Clin Pharmacol coronary artery Cruickshank JM decrease diastolic diastolic hypertensive diuretic dose double-blind drugs dysfunction effects of bisoprolol efﬁcacy ejection fraction elderly enalapril end-points Engl ﬁbrillation ﬁrst ﬁrst-line heart failure heart rate hemodynamic HFREF hypertensive patients hypertrophy increase induced Inﬂuence inhibition insulin intravenous ischemic JAMA labetalol Lancet left ventricular levels losartan low-dose metabolic metoprolol middle-aged mortality muscle nebivolol nifedipine nonselective noradrenaline obese oral oxprenolol pindolol placebo placebo-controlled plasma propranolol randomized receptor reduced renal renin risk second-line signiﬁcant signiﬁcantly sotalol stroke surgery sympathetic nerve activity syndrome systolic HF systolic hypertension tachycardia therapy timolol treatment type 2 diabetes UKPDS vascular ventricular arrhythmias young/middle-aged